Chronic Kidney Disease (CKD): Symptoms, Stages, Causes and Treatment Guide
- Dr. Ryan Heals, Pharm.D.
- 7 days ago
- 9 min read
Introduction of Chronic Kidney Disease (CKD)
Chronic kidney disease (CKD) is one of the most common — and most underrecognised — chronic conditions in the United States. According to the CDC's March 2026 data update, more than 1 in 10 adults — approximately 35.5 million Americans, around 14% of the adult population — are currently living with CKD. What makes this figure particularly alarming is that most people with CKD have no idea they have it. Because the kidneys have remarkable compensatory capacity, significant kidney damage can occur silently — with no symptoms at all — until the majority of function has already been lost.
CKD is not just a kidney problem. It dramatically increases the risk of heart attack, stroke, and cardiovascular death — so much so that most people with CKD die of cardiovascular disease before they ever reach kidney failure. It is also a major cause of anaemia, bone disease, and poor quality of life.
The treatment landscape for CKD has changed significantly in recent years. SGLT-2 inhibitors — originally developed for diabetes — are now established kidney-protective agents with compelling evidence regardless of whether diabetes is present. Understanding CKD, catching it early, and slowing its progression is now more achievable than ever.
This complete guide covers what CKD is, how it is staged, what causes it, how it is diagnosed, and the full evidence-based 2026 treatment approach.
The NIDDK provides comprehensive CKD patient information at: https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd
What the Kidneys Do — and What Happens When They Fail
The kidneys perform several vital functions:
Filter approximately 200 litres of blood per day, removing waste products (urea, creatinine, uric acid) and excess fluid as urine
Regulate blood pressure through the renin-angiotensin-aldosterone system (RAAS) and fluid balance
Produce erythropoietin (EPO) — the hormone that stimulates red blood cell production; CKD causes anaemia when EPO production falls
Activate vitamin D — essential for calcium absorption and bone health; CKD causes metabolic bone disease
Regulate electrolytes — potassium, phosphate, bicarbonate, and sodium balance
When kidney function declines, all of these functions are impaired — explaining the wide-ranging systemic consequences of CKD.
The 5 Stages of CKD — Based on eGFR
CKD is classified by eGFR (estimated Glomerular Filtration Rate) — a blood test measuring how well the kidneys are filtering, calculated from serum creatinine, age, and sex. The CKD-EPI 2021 equation (without race adjustment) is the current standard:
Stage | eGFR (mL/min/1.73 m²) | Description | Typical Symptoms |
Stage 1 | 90 or above | Normal or high eGFR with kidney damage markers | Usually none — detected by urine protein or imaging |
Stage 2 | 60–89 | Mildly reduced | Usually none |
Stage 3a | 45–59 | Mildly to moderately reduced | May begin — fatigue, mild anaemia |
Stage 3b | 30–44 | Moderately to severely reduced | Fatigue, anaemia, fluid retention beginning |
Stage 4 | 15–29 | Severely reduced | More prominent symptoms; prepare for renal replacement therapy |
Stage 5 | Below 15 | Kidney failure (End-Stage Renal Disease — ESRD) | Uraemic symptoms; dialysis or transplant required |
Albuminuria (protein in the urine) is assessed alongside eGFR — the combination determines prognosis more accurately than eGFR alone. Even a mildly reduced eGFR with heavy proteinuria carries higher risk than a similar eGFR without protein.
The NIDDK's comprehensive guide to what CKD is and how it is detected is available at: https://www.niddk.nih.gov/health-information/kidney-disease/chronic-kidney-disease-ckd/what-is-chronic-kidney-disease
Symptoms of CKD — Why It Is So Often Missed
The insidious nature of CKD is that symptoms typically do not appear until Stage 3b or beyond — by which point substantial irreversible damage has already occurred:
Early stages (1–3a) — usually no symptoms:
CKD is detected only through blood tests (elevated creatinine, low eGFR) or urine tests (proteinuria, haematuria) — often found incidentally on routine health checks.
Later stages (3b–4) — symptoms begin:
Fatigue and weakness — the most common early symptom; driven by anaemia (low EPO production) and accumulating uraemic toxins
Swelling (oedema) — in legs, ankles, and around the eyes; from fluid retention
Shortness of breath — from fluid in the lungs and anaemia
Reduced or changed urination — either increased frequency (especially at night — nocturia) or decreased output as function declines
Foamy urine — a sign of significant proteinuria
Loss of appetite and nausea
Stage 5 — uraemic symptoms (kidney failure):
Persistent nausea and vomiting
Severe fatigue and confusion
Muscle cramps and restless legs
Itching (uraemic pruritus) — from phosphate accumulation in the skin
Metallic taste in the mouth
Marked fluid overload — breathlessness, severe oedema
Without dialysis or transplant: life-threatening
What Causes CKD?
According to the CDC's 2026 update, diabetes and high blood pressure remain the two leading causes of end-stage kidney disease in the US, together accounting for over 70% of all new ESRD cases:
Diabetes (most common cause):
Diabetic nephropathy — kidney disease caused by diabetes — results from chronic hyperglycaemia damaging the tiny blood vessels (glomeruli) that filter the blood. The earliest sign is microalbuminuria (small amounts of protein in urine). Approximately 1 in 3 people with diabetes will develop CKD. Tight blood glucose control and blood pressure management dramatically slow progression.
High blood pressure (second most common):
Hypertension damages the blood vessels supplying the kidneys, progressively reducing their filtering capacity. CKD and hypertension have a destructive bidirectional relationship — CKD raises blood pressure, and high blood pressure accelerates CKD progression.
Other important causes:
Glomerulonephritis — inflammation of the kidney's filtering units; multiple types (IgA nephropathy is the most common worldwide)
Polycystic kidney disease (PKD) — the most common genetic cause; fluid-filled cysts progressively replace kidney tissue
Recurrent urinary tract infections and kidney infections — leading to scarring (reflux nephropathy)
Lupus nephritis — kidney involvement in systemic lupus erythematosus
Medication nephrotoxicity — NSAIDs (ibuprofen, naproxen), contrast dyes, certain antibiotics, and lithium are important modifiable causes
Obesity — now recognised as an independent CKD risk factor through hyperfiltration and metabolic mechanisms
Smoking — accelerates CKD progression in all aetiologies
Diagnosing CKD — The Two Key Tests
CKD is diagnosed by two tests performed on at least two occasions at least 3 months apart (confirming chronicity):
1. Blood test — eGFR:
Calculated from serum creatinine using the CKD-EPI 2021 equation. eGFR below 60 mL/min/1.73 m² on two occasions 3+ months apart confirms CKD. Normal eGFR is approximately 90–120.
2. Urine test — Albumin-to-Creatinine Ratio (ACR):
Detects proteinuria — protein leaking into urine, a marker of glomerular damage. ACR above 30 mg/g confirms clinically significant albuminuria. Proteinuria is both a diagnostic marker and a major driver of CKD progression — it is directly toxic to tubular cells.
Additional investigations:
Renal ultrasound — assesses kidney size (small scarred kidneys in chronic disease; large cystic kidneys in PKD), structure, and obstruction
Full blood count — screens for anaemia of CKD
Electrolytes (potassium, bicarbonate, phosphate, calcium) — managed as CKD progresses
Parathyroid hormone (PTH) — elevated in CKD-mineral bone disease
Specialist investigations for cause — anti-GBM, ANCA, ANA, complement levels for glomerulonephritis
Treatment of CKD — The 2026 Approach
There is no cure for CKD — but progression can be significantly slowed with the right interventions, reducing the risk of both kidney failure and cardiovascular death:
Blood pressure control — the most important intervention:
Target blood pressure below 120/80 mmHg in most CKD patients (per 2026 guidelines)
ACE inhibitors (lisinopril, ramipril) or ARBs (losartan, irbesartan) are first-line antihypertensives in CKD — they reduce proteinuria and provide direct kidney-protective effects beyond blood pressure lowering via RAAS blockade
ACE inhibitors and ARBs must NOT be combined (dual RAAS blockade increases harm)
SGLT-2 inhibitors — the landmark advance:
SGLT-2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) were originally developed for Type 2 diabetes but have proven to be kidney-protective independent of blood glucose effects. The CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials established compelling evidence:
Dapagliflozin — FDA-approved for CKD in non-diabetic patients in 2021; the first new drug class for CKD in decades
Reduces the risk of kidney failure, cardiovascular events, and death in CKD by approximately 40% in high-risk patients
Now recommended in 2026 KDIGO guidelines for all CKD patients with eGFR 20+ and significant albuminuria regardless of diabetes status
Finerenone (non-steroidal MRA):
A new non-steroidal mineralocorticoid receptor antagonist — FDA-approved 2021 for CKD in Type 2 diabetes with albuminuria; the FIDELIO and FIGARO trials showed significant kidney and cardiovascular protection alongside ACE inhibitors.
Blood glucose control (in diabetic CKD):
Maintaining HbA1c below 7% (individualised target) slows diabetic nephropathy progression significantly. GLP-1 receptor agonists (semaglutide) also have kidney-protective effects now being incorporated into 2026 guidelines.
Dietary management:
Protein restriction — 0.6–0.8g/kg/day in advanced CKD reduces uraemic toxin production and hyperfiltration injury
Sodium restriction — below 2g/day; reduces blood pressure and oedema
Potassium restriction — in later stages when hyperkalaemia risk rises
Phosphate restriction — prevents renal bone disease (phosphate binders prescribed in Stage 4–5)
Adequate hydration — avoid dehydration which worsens CKD acutely
Anaemia management:
Iron supplementation — iron deficiency is extremely common in CKD
ESAs (erythropoiesis-stimulating agents) — EPO analogues (epoetin alfa, darbepoetin) for CKD anaemia when iron-replete; target haemoglobin 10–11.5 g/dL
HIF-PHI (hypoxia-inducible factor prolyl hydroxylase inhibitors) — newer oral agents (daprodustat, roxadustat) for CKD anaemia; approved in some countries
Renal replacement therapy (Stage 5):
Haemodialysis — blood filtered by machine 3x weekly in-centre or at home
Peritoneal dialysis — fluid exchanges through a catheter into the abdomen; can be done at home
Kidney transplant — the most effective treatment for ESRD; significantly better survival and quality of life than dialysis
CKD Medicines Comparison Table
Medicine / Class | Role in CKD | Evidence | Key Notes |
ACE inhibitors (Lisinopril, Ramipril) | First-line BP + kidney protection | Very strong | Reduces proteinuria; monitor potassium |
ARBs (Losartan, Irbesartan) | First-line BP + kidney protection (ACE intolerant) | Very strong | Same benefits as ACE; do not combine with ACE |
SGLT-2 inhibitors (Dapagliflozin, Empagliflozin) | Kidney + cardiovascular protection | Landmark — DAPA-CKD, EMPA-KIDNEY | FDA-approved for CKD regardless of diabetes |
Finerenone | CKD with T2D + albuminuria | Strong — FIDELIO, FIGARO | Non-steroidal MRA; less hyperkalaemia than spironolactone |
GLP-1 agonists (Semaglutide) | Glycaemic + kidney protection in T2D-CKD | Growing — 2026 KDIGO integration | Also causes weight loss |
Phosphate binders | Prevent renal bone disease (Stage 4–5) | Standard of care | Calcium carbonate, sevelamer, lanthanum |
ESAs (Epoetin, Darbepoetin) | CKD anaemia | Standard of care | Target Hb 10–11.5 g/dL; iron-replete first |
For our complete guide on Type 2 diabetes — the leading cause of CKD: [Type 2 Diabetes: Symptoms, Causes and Treatment]
For our guide on high blood pressure — the second leading cause of CKD and always coexisting: [High Blood Pressure (Hypertension): Complete Guide]
For our guide on UTIs — recurrent kidney infections are an important and preventable cause of CKD progression: [UTI: Symptoms, Causes and Treatment Guide]
Current 2026 CKD data from the CDC is available at: https://www.cdc.gov/kidney-disease/php/data-research/index.html
Frequently Asked Questions
Can CKD be reversed?
In most cases, established CKD — particularly at Stage 3 and above — cannot be fully reversed because kidney damage involves irreversible scarring (fibrosis). However, the critical goal of treatment is to slow or halt progression rather than cure. Some cases of CKD caused by reversible triggers — such as medication toxicity, urinary obstruction, or certain glomerulonephritides — can improve significantly when the underlying cause is removed. Early-stage CKD (Stage 1–2) in particular may stabilise for many years with optimal management.
What foods should I avoid with CKD?
Dietary modifications in CKD depend on the stage and the individual's blood test results. General principles include limiting sodium (below 2 grams per day to control blood pressure and fluid retention), restricting phosphate in later stages to protect bones (avoiding processed foods, dark cola drinks, and many dairy products), and managing potassium in Stages 4–5 if blood levels are elevated (avoiding bananas, oranges, potatoes, and tomatoes in excess). Protein restriction of 0.6 to 0.8 grams per kilogram of body weight per day is generally recommended in Stages 3b to 5 to reduce uraemic toxin production. A specialist renal dietitian should guide dietary changes in moderate to advanced CKD.
How do I know if my kidneys are failing?
Kidney failure (Stage 5 CKD) produces the following warning signs: severe persistent fatigue and confusion, nausea and vomiting with loss of appetite, significant fluid retention causing breathlessness and swelling, very dark or very reduced urine output, metallic taste, and persistent itching. However, the crucial point is that most people feel well until very late stage CKD. The only reliable way to know your kidney function is a blood test (eGFR). Anyone with diabetes, hypertension, or a family history of kidney disease should be tested annually.
Is CKD hereditary?
Some forms of CKD are directly inherited — polycystic kidney disease (PKD) is the most common inherited kidney disorder, following an autosomal dominant pattern and affecting approximately 1 in 500 to 1 in 1,000 people. Alport syndrome and certain types of IgA nephropathy also have genetic components. Additionally, the risk factors for CKD — particularly diabetes and hypertension — run in families. A family history of kidney failure in a first-degree relative significantly increases lifetime CKD risk.
Can I take ibuprofen if I have CKD?
No — NSAIDs such as ibuprofen and naproxen should be avoided in CKD wherever possible. NSAIDs reduce blood flow to the kidneys by blocking prostaglandins, causing acute kidney injury on top of existing CKD and accelerating long-term progression. Even short-term use can cause significant acute deterioration in CKD patients, particularly if they are also on ACE inhibitors or diuretics. Paracetamol (acetaminophen) is the preferred simple analgesic in CKD at standard doses.
Comments